Secretive biotech company R3 Bio is advancing a controversial project: cultivating unconscious human clones ("organ pods") through gene-editing technology, aiming to replace animal testing and address organ shortages. Led by CEO Alice Gilman and founder John Schloendorn, the project has secured capital support from billionaire Tim Draper, Singaporean investment fund Immortal Dragons, and LongGame Ventures, which focuses on longevity. Its core concept involves cultivating clones with only the minimal brain structures required to sustain life, serving as spare bodies for organ transplants or even full-body replacements. While R3 Bio claims to have developed molecular techniques to enhance cloning success rates, the high rates of deformities in mammalian cloning and the absence of artificial womb technology still pose significant challenges. The scientific community strongly rejects the project, with ethical controversies focusing on the vague definition of 'unconsciousness,' the potential for basic consciousness in the brainstem, and the legal accusations that may arise from harvesting organs.